|Articles|October 15, 2001
- BioPharm International-10-01-2001
- Volume 14
- Issue 10
Inside Washington: Crisis and Costs Grip Biotech Industry
Author(s)Jill Wechsler
by Jill Wechsler Terrorist attack may postpone health policy legislation but encourage antibioterrorism initiatives.
Advertisement
Articles in this issue
over 24 years ago
Statistical Tools for Setting In-Process Acceptance Criteriaover 24 years ago
Managing Your Career: Recruiter-Proof Your Organizationover 24 years ago
Outsourcing OutlookNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
2
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
3
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
4
High-Dose Nusinersen Slows Neurodegeneration in SMA Patients, Study Shows
5
